Drug Information

Drug General Information
Drug ID
D0T5AW
Former ID
DIB004852
Drug Name
Desoxypeganine
Synonyms
Alcoholism therapy, HF Arzneimittelforschung; Desoxypeganine, HF Arzneimittelforschung
Drug Type
Small molecular drug
Indication Alcohol use disorders [ICD9: 303; ICD10:F10.2] Phase 1 [529540]
Company
HF Arzneimittelforschung GmbH & Co KG
Formula
C11H12N2
Canonical SMILES
N1=C2N(Cc3c1cccc3)CCC2
CAS Number
CAS 495-59-0
PubChem Compound ID
442894
Target and Pathway
Target(s) Acetylcholinesterase Target Info Modulator [529540]
Amine oxidase [flavin-containing] A Target Info Modulator [529540]
BioCyc Pathway Superpathway of tryptophan utilization
Dopamine degradation
Putrescine degradation III
Noradrenaline and adrenaline degradation
Serotonin degradation
Superpathway of melatonin degradation
Melatonin degradation II
KEGG Pathway Glycerophospholipid metabolism
Cholinergic synapsehsa00260:Glycine, serine and threonine metabolism
Arginine and proline metabolism
Histidine metabolism
Tyrosine metabolism
Phenylalanine metabolism
Tryptophan metabolism
Drug metabolism - cytochrome P450
Metabolic pathways
Serotonergic synapse
Dopaminergic synapse
Cocaine addiction
Amphetamine addiction
Alcoholism
NetPath Pathway IL4 Signaling Pathway
PANTHER Pathway Muscarinic acetylcholine receptor 1 and 3 signaling pathway
Muscarinic acetylcholine receptor 2 and 4 signaling pathway
Nicotinic acetylcholine receptor signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
5-Hydroxytryptamine degredation
Dopamine receptor mediated signaling pathway
Pathway Interaction Database ATF-2 transcription factor network
PathWhiz Pathway Phospholipid BiosynthesisPW000043:Histidine Metabolism
Tyrosine Metabolism
Glycine and Serine Metabolism
Reactome Norepinephrine Neurotransmitter Release Cycle
WikiPathways Monoamine Transport
Biogenic Amine Synthesis
Acetylcholine Synthesis
Integrated Pancreatic Cancer PathwayWP706:SIDS Susceptibility Pathways
Oxidative Stress
Dopamine metabolism
Phase 1 - Functionalization of compounds
Neurotransmitter Release Cycle
Neurotransmitter Clearance In The Synaptic Cleft
Serotonin Transporter Activity
References
Ref 529540Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
Ref 529540Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.